Press-release for stocks publishing date 2021 - 12

Prices are updated after-hours

publishing date : 2021 - 12 - 13 source : Www.biospace.com

save search

Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
Published: 2021-12-13 (Crawled : 23:00) - biospace.com/
TRVN | $0.3702 5.17% 5.88% 420K

Health Technology

| -45.91% | O: 6.24% H: 0.0% C: 0.0%
trv045 diabetic diabetes

Teleflex Receives Reimbursement Approval for the UroLift® System in JapanWill expand patient access to breakthrough BPH treatment
Published: 2021-12-13 (Crawled : 23:00) - biospace.com/
TFX | $207.27 0.34% 0.0% 330K

Health Technology

| -35.49% | O: -0.09% H: 0.0% C: 0.0%
urolift treatment approval

Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613
Published: 2021-12-13 (Crawled : 23:00) - biospace.com/
SNDX | $20.96 0.77% 0.81% 670K

Health Technology

| 19.09% | O: -6.48% H: 18.59% C: 10.02%
gment-101 als 613 trial phase 1 positive

Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual MeetingPreliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients
Published: 2021-12-13 (Crawled : 23:00) - biospace.com/
BPTH | $2.92 -31.94% -45.18% 21K

Health Technology

| -37.34% | O: -9.01% H: 0.0% C: 0.0%
ema phase 2 ongoing risk aml

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
CMPS | $8.36 -0.24% -0.6% 350K

Health Technology

| -68.32% | O: -5.04% H: 0.0% C: 0.0%
comp360 treatment positive therapy depression psilocybin

ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
ORIC | $8.72 -5.11% -5.51% 270K

Health Technology

| -39.49% | O: 1.67% H: 0.0% C: 0.0%
oric-533 ema als potential

Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
FATE | News | $4.78 -0.21% -0.21% 890K

Health Technology

| -90.28% | O: -0.1% H: 0.0% C: 0.0%
ft596 therapeutics phase 1 positive t-cell

Avanos Medical, Inc. Announces Agreement To Acquire OrthogenRx, Inc.
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
AVNS | $18.95 1.28% 0.0% 190K

Health Technology

| -35.94% | O: -0.78% H: 0.0% C: 0.0%

CSL and Vifor Confirm Advanced Talks of Potential $8 Billion+ Acquisition
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
MS | News | $92.09 1.58% 0.07% 4.9M

Finance

| -8.69% | O: -2.95% H: 0.0% C: 0.0%
acquisition potential

Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 2.1K

Health Technology

| -4.6% | O: -0.09% H: 0.0% C: 0.0%
zuma-12 yescarta treatment risk t-cell

Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
ALLO | $3.4 -2.02% -2.36% 1.8M

Health Technology

| -81.14% | O: 1.05% H: 2.52% C: -22.56%
allo-715 ema therapeutics positive results phase 1 positive therapy results t-cell

Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
ALLO | $3.4 -2.02% -2.36% 1.8M

Health Technology

| -81.14% | O: 1.05% H: 2.52% C: -22.56%
ema als trials trial therapeutics phase 1 positive

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
VIRX | $0.88 2.72% -3.3% 14K

Manufacturing

| -79.05% | O: -2.86% H: 0.0% C: 0.0%
phase 1b therapeutics presentation phase 1 positive phase 2b

Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
AGIO | $30.21 2.3% 2.25% 860K

Health Technology

| 2.13% | O: 0.61% H: 0.0% C: 0.0%
transfusion

Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
KURA | News | $18.19 3.77% 3.79% 18

Health Technology

| 48.85% | O: 3.03% H: 0.0% C: 0.0%
phase 2 results t-cell

CareDx Partners with the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Organization in Launching Prospective, Multi-Center Pediatric Kidney Transplant Study
Published: 2021-12-13 (Crawled : 18:00) - biospace.com/
CDNA | $8.17 -1.69% -1.71% 480K

Health Technology

| -80.98% | O: 0.09% H: 0.0% C: 0.0%
als renal trials trial kidney

Neurona Therapeutics Announces C-Suite Leadership Team
Published: 2021-12-13 (Crawled : 18:00) - biospace.com/
GERN | $3.73 1.08% 1.07% 3.2K

Health Technology

| 184.73% | O: -0.76% H: 0.0% C: 0.0%
therapeutics

Inivata Appoints David Eberhard MD, PhD as Chief Medical Officer
Published: 2021-12-13 (Crawled : 18:00) - biospace.com/
NEO | $13.42 -0.81% -0.74% 800K

Health Services

| -59.93% | O: -4.4% H: 0.0% C: 0.0%